Get the latest news alerts: at Twitter.
Local Tech Wire
MORRISVILLE, N.C. – Startup sure came close – $999,999 – to raising a target of $1 million in debt financing, according to a Securities and Exchange Commission filing.
The filing was submitted this week.
Previously disclosed PhaseBio investors include Fletcher Spaght Venture Partners, Hatteras Venture Partners and Johnson and Johnson Development Corporation.
The company borrowed $1 million a year ago to move its headquarters.
Christopher Prior joined the firm as its chief executive officer in April of last year.
PhaseBio also licensed drug-discovery technology from Duke University in 2008. The company also has its own drug-purification and delivery-process technology. It closed on $5.4 million in venture funding as part of a $6.6 million Series B round in 2007.
